Cargando…

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection

Detalles Bibliográficos
Autores principales:	Havervall, Sebastian, Marking, Ulrika, Svensson, Julia, Greilert-Norin, Nina, Bacchus, Philip, Nilsson, Peter, Hober, Sophia, Gordon, Max, Blom, Kim, Klingström, Jonas, Åberg, Mikael, Smed-Sörensen, Anna, Thålin, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511632/ https://www.ncbi.nlm.nih.gov/pubmed/36103621 http://dx.doi.org/10.1056/NEJMc2209651

Ejemplares similares

Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose
por: Bladh, Oscar, et al.
Publicado: (2023)

7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection
por: Marking, Ulrika, et al.
Publicado: (2023)

Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers
por: Marking, Ulrika, et al.
Publicado: (2023)

Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection
por: Blom, Kim, et al.
Publicado: (2022)

Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022
por: Blom, Kim, et al.
Publicado: (2022)

Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time
por: Havervall, Sebastian, et al.
Publicado: (2022)

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines
por: Marking, Ulrika, et al.
Publicado: (2022)

Point prevalence of SARS-CoV-2 infection among healthcare workers in March and June 2023 in Sweden
por: Blom, Kim, et al.
Publicado: (2023)

Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2
por: Havervall, Sebastian, et al.
Publicado: (2021)

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19
por: Havervall, Sebastian, et al.
Publicado: (2021)

An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses
por: Mangsbo, Sara M., et al.
Publicado: (2021)

Rapid emergence of omicron sublineages expressing spike protein R346T
por: Groenheit, Ramona, et al.
Publicado: (2022)

A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies
por: Mravinacova, Sara, et al.
Publicado: (2022)

SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection
por: Havervall, Sebastian, et al.
Publicado: (2022)

Long‐term SARS‐CoV‐2‐specific and cross‐reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology
por: Laurén, Ida, et al.
Publicado: (2022)

High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022
por: Groenheit, Ramona, et al.
Publicado: (2023)

IL-6 signalling biomarkers in hospitalised patients with moderate to severe SARS-CoV-2 infection in a single centre study in Sweden
por: Ziegler, Louise, et al.
Publicado: (2022)

The mucosal immune system and IgA nephropathy
por: Gesualdo, Loreto, et al.
Publicado: (2021)

Omicron Spike Protein is Vulnerable to Reduction
por: Yao, Zhong, et al.
Publicado: (2023)

Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody
por: Yin, Wanchao, et al.
Publicado: (2022)

Impact of monocyte‐related modulators and kidney function on mortality in hospitalized patients with COVID‐19
por: Sendic, Senka, et al.
Publicado: (2022)

“Role of kidney function and concentrations of BAFF, sPD-L1 and sCD25 on mortality in hospitalized patients with COVID-19”
por: Mansouri, Ladan, et al.
Publicado: (2022)

The Effects of Secretory IgA in the Mucosal Immune System
por: Li, Yue, et al.
Publicado: (2020)

Innate and adaptive immune responses against human Puumala virus infection: immunopathogenesis and suggestions for novel treatment strategies for severe hantavirus‐associated syndromes
por: Klingström, J., et al.
Publicado: (2019)

On the Origins of Omicron’s Unique Spike Gene Insertion
por: Venkatakrishnan, A. J., et al.
Publicado: (2022)

Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma
por: Zenlander, Robin, et al.
Publicado: (2021)

Multi-Faceted Functions of Secretory IgA at Mucosal Surfaces
por: Corthésy, Blaise
Publicado: (2013)

Mucosal Immune System Dysregulation in the Pathogenesis of IgA Nephropathy
por: Kano, Toshiki, et al.
Publicado: (2022)

There is nothing exempt from the peril of mutation – The Omicron spike
por: Behl, Tapan, et al.
Publicado: (2022)

Emergence of Genomic Diversity in the Spike Protein of the “Omicron” Variant
por: Basak, Surajit, et al.
Publicado: (2023)

Structural and functional impact by SARS-CoV-2 Omicron spike mutations
por: Zhang, Jun, et al.
Publicado: (2022)

Royal jelly enhances antigen‐specific mucosal IgA response
por: Kai, Hikaru, et al.
Publicado: (2013)

Mucosal linear IgA disease with esophageal involvement responsive to ustekinumab
por: Jimenez, Amber, et al.
Publicado: (2021)

Structures of Omicron spike complexes and implications for neutralizing antibody development
por: Guo, Hangtian, et al.
Publicado: (2022)

Structural diversity of the SARS-CoV-2 Omicron spike
por: Gobeil, Sophie M.-C., et al.
Publicado: (2022)

Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
por: Mao, Tianyang, et al.
Publicado: (2022)

Systemic administration of an HIV 1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization
por: Fouda, Genevieve G., et al.
Publicado: (2016)

In rheumatoid arthritis patients, total IgA1 and IgA2 levels are elevated: implications for the mucosal origin hypothesis
por: Derksen, Veerle F A M, et al.
Publicado: (2022)

Elevated factor V activity and antigen levels in patients with Covid‐19 are related to disease severity and 30‐day mortality
por: von Meijenfeldt, Fien A., et al.
Publicado: (2021)

Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge
por: von Meijenfeldt, Fien A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_blokrqk9d9hvm5odo3ncigom64